US-based digital healthcare aggregator WellSync has teamed up with Marius Pharmaceuticals to offer Marius’ Kyzatrex (testosterone undecanoate) capsules on its virtual care platform.
Kyzatrex is an oral form of testosterone replacement therapy (TRT) used to treat adult males with hypogonadism, a condition characterised by low or no testosterone.
WellSync said that its virtual-first platform handles every aspect of the patient journey, from initial lab services to virtual consultations, personalised treatment, and medication fulfilment.
WellSync CEO Clint House said: “Our work with Marius Pharmaceuticals represents a significant step forward in our mission to transform the way healthcare is delivered.
“By offering Kyzatrex through our virtual care platform, we’re delivering a streamlined, accessible, and effective solution for men’s health that seamlessly integrates into our clients’ existing offerings.
“Additionally, we’re creating a new marketplace for brand manufacturers to leverage our platform to launch their innovative treatments.”
WellSync said that the addition of Kyzatrex to its programmes will complement its goal of improving access to care while supporting new medications using its direct-to-consumer platform.
The digital healthcare company will review the orders and ship them directly to the patient’s doorstep through a URAC-accredited partner pharmacy, pending approval.
The end-to-end virtual care platform enables drug manufacturers like Marius Pharmaceuticals to reach patients more effectively and at a reasonable price.
Also, the platform ensures that TRT medications like Kyzatrex are delivered with the highest level of care and convenience, said WellSync.
Marius Pharmaceuticals CEO Shalin Shah said: “By offering Kyzatrex through WellSync’s platform, we’re simplifying the process for men to manage their testosterone levels. This effort is an important step toward enhancing healthcare accessibility and improving patient outcomes.”
House added: “This collaboration with Marius Pharmaceuticals underscores our commitment to working with leading pharmaceutical companies to bring cutting-edge treatments directly to patients, enhancing their health and well-being.”
